Chart, page-3020

You may like to articulate what you mean by "binary outcome" in terms of the what outcome and when? I find this term gets way overused as it neglects to look at timeframes involved and all the stuff that happens between time.

For example, there is potentially lots of re-rate catalysts that will occur before we're likely to see read out of OA_002. Moreover, it would seem statistically improbable for it to now contradict +700 existing patient outcomes via SAS/NFL.

Perhaps some may see "binary outcome" through a lens of FDA allowing DM labelling on receipt of NDA approval....which we may get more insight into by late Sept.

But to me I'm totally focused on safety and efficacy (pain and function). This alone allows us to create an OA market that will easily rival the current RA market.